PLK1 inhibitors also synergistically with mTOR inhibitors to compensatively induce MYC expression, overcome the oxaliplatin resistance of colon cancer, and enhance the radiosensitivity of medulloblastoma (6, 45, 46). Here, PLK1 is linked to colonic neoplasm.